The gene therapy market is characterized by a healthy drug pipeline, with 10 approved molecules and over 820 product candidates {Roots Analysis}

Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.

 

To order this 720+ page report, which features 220+ figures and 375+ tables, please visit thishttps://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

The USD 14.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

  • Therapeutic approach
  • Gene augmentation
  • Oncolytic therapy
  • Immunotherapy
  • Others

 

  • Type of gene therapy
  • Ex vivo
  • In vivo

 

  • Type of vector used
  • Adeno associated virus
  • Adenovirus
  • Herpes simplex virus
  • Lentivirus
  • Plasmid DNA
  • Retrovirus
  • Others

 

  • Key therapeutic areas
  • Autoimmune disorders
  • Cardiovascular diseases
  • Dermatological disorders
  • Genetic disorders
  • Hematological disorders
  • Metabolic disorders
  • Muscle-related diseases
  • Oncological disorders
  • Ophthalmic diseases
  • Others

 

  • Route of administration
  • Intraarticular
  • Intracerebellar
  • Intradermal
  • Intramuscular
  • Intratumoral
  • Intravenous
  • Intravesical
  • Intravitreal
  • Subretinal
  • Others

 

  • Key geographical regions
  • North America
  • Europe
  • Asia-Pacific

 

The Gene Therapy Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Abeona Therapeutics
  • Advantagene
  • Biogen
  • bluebird bio
  • Castle Creek Biosciences
  • CG Oncology
  • FerGene
  • Freeline Therapeutics
  • Gradalis
  • Helixmith
  • Inovio Pharmaceuticals
  • Kolon TissueGene
  • Krystal Biotech
  • Lysogene
  • Neurophth Therapeutics
  • OncoSec Immunotherapies
  • Orchard Therapeutics
  • Pfizer
  • Sangamo Therapeutics
  • Spark Therapeutics
  • uniQure Biopharma
  • VBL Therapeutics

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Gene Delivery Vectors
  4. Regulatory Landscape and Reimbursement Scenario
  5. Market Overview
  6. Competitive Landscape
  7. Marketed Gene Therapies
  8. Key Commercialization Strategies
  9. Late Stage (Phase II/III and Above) Gene Therapies
  10. Emerging Technologies
  11. Key Therapeutics Areas
  12. Patent Analysis
  13. Mergers and Acquisitions

 

  1. Funding and Investment Analysis

 

  1. Clinical Trial Analysis

 

  1. Cost Price Analysis

 

  1. Big Pharma Players: Analysis of Gene Therapy Related Initiatives

 

  1. Demand Analysis

 

  1. Market Forecast and Opportunity Analysis

 

  1. Vector Manufacturing

 

  1. Case Study: Gene Therapy Supply Chain

 

  1. Conclusion

 

  1. Interview Transcripts

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com